Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfaguanidine is a sulfonamide antibiotic and a guanidine derivative of sulfanilamide, primarily used in veterinary medicine and formerly in human medicine for the treatment of gastrointestinal bacterial infections such as bacillary dysentery. It is characterized by poor absorption from the gut, which allows it to act locally within the intestinal tract. The drug exerts its antibacterial effect by inhibiting dihydropteroate synthase, thereby blocking the synthesis of dihydrofolic acid from para-aminobenzoic acid (PABA) in bacteria. This mechanism disrupts folic acid synthesis, leading to bacteriostatic activity against susceptible organisms[1][4][8]. Sulfaguanidine was introduced in 1940 and has been widely used for enteric infections due to its minimal systemic absorption[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfaguanidine.